Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care

Next Previous
Trial Profile

An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Pharmacodynamics; Registrational
  • Acronyms ASTEROID 6
  • Sponsors Bayer

Most Recent Events

  • 27 Aug 2024 Status changed from completed to discontinued.
  • 24 Dec 2021 Trial has been completed in Finland.
  • 23 Nov 2021 Planned End Date changed from 29 Oct 2021 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top